医学
苯拉唑马布
哮喘
随机对照试验
安慰剂
恶化
人口
临床终点
内科学
美波利祖马布
嗜酸性粒细胞
替代医学
环境卫生
病理
作者
Kefang Lai,Dejun Sun,Ranran Dai,Ronnie Samoro,Hae‐Sim Park,Annika Åstrand,David Cohen,Maria Jison,Vivian H. Shih,Viktoría Werkström,Yuhui Yao,Yajuan Zhang,Wenying Zheng,Nanshan Zhong
标识
DOI:10.1016/j.rmed.2024.107611
摘要
BACKGROUND: Benralizumab is indicated as add-on therapy in patients with uncontrolled, severe eosinophilic asthma; it has not yet been evaluated in a large Asian population with asthma in a clinical trial. OBJECTIVE: To evaluate the efficacy and safety of benralizumab in patients with severe asthma in Asia. METHODS: ) and total asthma symptom score (TASS). Safety was evaluated ≤ Week 56. RESULTS: , and TASS with benralizumab versus placebo. The frequency of adverse events was similar for benralizumab (76%) and placebo (80%) in the overall population. CONCLUSIONS: MIRACLE data reinforces the efficacy and safety of benralizumab for severe eosinophilic asthma in an Asian population, consistent with the global Phase 3 results.
科研通智能强力驱动
Strongly Powered by AbleSci AI